Protective properties of non-nucleoside reverse transcriptase inhibitor (MC1220) incorporated into liposome against intravaginal challenge of Rhesus macaques with RT-SHIV.
In the absence of an effective vaccine against HIV, it is urgent to develop an effective alternative such as a microbicide. Single and repeated applications of MC1220 microbicide were evaluated in macaques. First, animals were given a single application of 0.5% or 1.5% MC1220-containing liposomal gel. A second group were treated with 0.5% MC1220 once a day for 4 days. The control groups were treated by liposomal gel alone. Thirty minutes after the last application, animals were challenged with RT-SHIV. In the first protocol, 2 of 4 animals treated by 0.5% of the MC1220 and 2 of 5 treated by 1.5% were protected. In the second protocol, 3 of 5 treated animals were protected and 5 of 5 controls were infected. The RNA viral load at necropsy was significantly lower (p=0.05) in treated-infected animals than in controls. In both protocols, the number of CD4+ T cells was lower at viremia peak in infected than in protected animals.
Caron
Mélanie
M
Unité de Retrovirologie, Centre International de Recherches Médicales de Franceville, Franceville, BP 769, Gabon.
Besson
Guillaume
G
Etenna
Sonia Lekana-Douki
SL
Mintsa-Ndong
Armel
A
Mourtas
Spyridon
S
Radaelli
Antonia
A
Morghen
Carlo De Giuli
Cde G
Loddo
Roberta
R
La Colla
Paolo
P
Antimisiaris
Sophia G
SG
Kazanji
Mirdad
M
D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D005260:Female; D005464:Fluorobenzenes; D005782:Gels; D006678:HIV / Q000187:drug effects* / Q000235:genetics; D008081:Liposomes; D008253:Macaca mulatta; D011744:Pyrimidinones / Q000009:adverse effects / Q000627:therapeutic use*; D016865:Reassortant Viruses; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D016097:Simian Acquired Immunodeficiency Syndrome / Q000517:prevention & control*; D015302:Simian Immunodeficiency Virus / Q000187:drug effects* / Q000235:genetics; D019562:Viral Load
C506288:6-(1-(2,6-difluorophenyl)ethyl)-2-(dimethylamino)-5-methylpyrimidin-4(3H)-one; D000914:Antibodies, Viral; D005464:Fluorobenzenes; D005782:Gels; D008081:Liposomes; D011744:Pyrimidinones; D018894:Reverse Transcriptase Inhibitors